[The new generation tool for CRISPR genome editing: CRISPR/Cpf1]

Area of Science:

• Molecular Biology
• Genetics
• Biotechnology

Background:

• CRISPR-Cas systems are crucial for adaptive immunity in archaea and bacteria.
• Cas9, a type II CRISPR nuclease, has been a revolutionary tool for genome editing since 2012.
• Current Cas9 applications face limitations including targeting range, toxicity, and off-target mutations.

Purpose of the Study:

• To review the development and applications of Cpf1, a distinct CRISPR RNA-guided endonuclease.
• To highlight Cpf1's potential to address current genome editing challenges.
• To discuss future directions for Cpf1-based research and applications.

Main Methods:

• Literature review of CRISPR-Cas systems, focusing on Cas9 and Cpf1.
• Comparative analysis of Cas9 and Cpf1 functionalities and applications.
• Exploration of Cpf1's distinct characteristics as a Class 2/Type V endonuclease.

Main Results:

• Cas9 has enabled widespread genome editing but presents limitations.
• Cpf1 (Class 2/Type V) offers a distinct mechanism compared to Cas9 (Type II).
• Cpf1 demonstrates potential for overcoming existing genome editing challenges.

Conclusions:

• Cpf1 represents a promising alternative or complementary tool to Cas9 for genome editing.
• Further research into Cpf1 strategies is expected to advance genome editing capabilities.
• Cpf1 holds potential for innovative applications in basic research, biotechnology, and medicine.